To include your compound in the COVID-19 Resource Center, submit it here.

Regulatory Milestones

Highlights of weekly biotech stock moves

Amgen Inc. (NASDAQ:AMGN) could move on Monday this week after the company announced late last Friday that it had submitted a BLA to FDA for denosumab to reduce skeletal related events (SREs) in cancer patients. Denosumab is already under review to treat postmenopausal osteoporosis, with a July 25 PDUFA. Amgen was up $0.23 to $54.69 last week.

Cadence Pharmaceuticals Inc. (NASDAQ:CADX) could move on Monday this week after the company announced late last Friday that FDA accepted an NDA resubmission for Ofirmev IV acetaminophen to treat pain and fever. The agency designated the

Read the full 920 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE